Investigating the relationship between ccfDNA concentration, its integrity, and some individual factors in an Iranian population

2020 ◽  
Vol 28 (4) ◽  
pp. 319-326
Author(s):  
Maryam Khani ◽  
Jalil Hosseini ◽  
Mohsen Habibi ◽  
Reza Mirfakhraie ◽  
Zahra Sadeghzadeh ◽  
...  

INTRODUCTION: Circulating cell-free DNA (ccfDNA) increases in some pathologic conditions like cancer. We aimed to investigate the correlation between some individual factors and the ccfDNA level in peripheral blood of Iranian in relation to prostate cancer. MATERIAL AND METHOD: 30 patients with prostate cancer (PCa), 40 with benign prostate hyperplasia (BPH), and 30 controls were studied. Personal information, ccfDNA concentration, and the integrity index were assessed for the correlation between the disease and different factors. The results were statistically analyzed using SPSS software. RESULTS: In PCa group, no association was found between total ccfDNA, BMI, BPH background, non-cancerous diseases, medications, PCa length, and job (p-value > 0.05). But, total ccfDNA had statistical associations with weight, family history of cancer, and location (p-value < 0.05). No association was between the integrity of ccfDNA, weight, the background of BPH, and family history of cancer. But, the integrity of ccfDNA was significantly associated with BMI and PCa length (p-value < 0.05). In BPH group, no association between total ccfDNA or the integrity of ccfDNA and the assessed factors was obtained (p-value > 0.05). In the normal group, neither statistical association was found between total ccfDNA, weight, BMI, and job, nor between the integrity of ccfDNA, weight, BMI, non-cancerous disease, drug, job, and location (p-value > 0.05). But, a statistical association was found between the integrity of ccfDNA and family history of cancer in the recent group (Based on 95% CI and P-value less than 0.05). CONCLUSION: ccfDNA and its integrity as possible prostate cancer biomarkers under the influence of individuals’ physiological status are prone to the pathologic changes toward the disease. Further simultaneous study of the target groups could clarify this matter.

1995 ◽  
Vol 60 (3) ◽  
pp. 361-364 ◽  
Author(s):  
Richard B. Hayes ◽  
Jonathan M Liff ◽  
Linda M. Pottern ◽  
Raymond S. Greenberg ◽  
Janet B. Schoenberg ◽  
...  

Urology ◽  
2002 ◽  
Vol 59 (4) ◽  
pp. 546-550 ◽  
Author(s):  
Terri M King ◽  
L Tong ◽  
Rebecca J Pack ◽  
Cheri Spencer ◽  
Christopher I Amos

1995 ◽  
Vol 1 (6) ◽  
pp. 240-245 ◽  
Author(s):  
Curtis Mettlin ◽  
Nachimuthu Natarajan ◽  
Robert Huben ◽  
Derek Raghavan

2002 ◽  
Vol 10 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Sally P. Weinrich ◽  
Louise Faison-Smith ◽  
Julie Hudson-Priest ◽  
Charmaine Royal ◽  
Isaac Powell

The genome-wide search for the prostate cancer gene holds the promise of the availability of prostate cancer susceptibility testing in the near future. When this occurs, self-reported history of prostate cancer will be critical in determining who is eligible for cancer susceptibility testing. Little attention has been given to the reliability of self-reported family history of prostate cancer, particularly in African American men. This correlational study measured the stability of self-reported family history of prostate cancer over a one-year time period (between 1997 and 1998) with 96 African American men from a southern state. The men were asked on two separate occasions, 1 year apart, “Have any of your men blood relatives ever had prostate cancer?” The question had a prior test-retest reliability of 0.85 over a 2-week period. Forty-eight percent of the men changed their answers on the second administration. Men most likely to change their answers were low-income men and men who did not participate in a free prostate cancer screening. This research highlights the need for public genetic education and the recognition by health professionals that self-reported family history of cancer is a variable that changes as families have increased awareness and communication concerning family history of cancer.


2005 ◽  
Vol 8 (1) ◽  
pp. 60-65 ◽  
Author(s):  
Y Bai ◽  
Y-T Gao ◽  
J Deng ◽  
I A Sesterhenn ◽  
J F Fraumeni ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10599-10599
Author(s):  
Catherine Travaline ◽  
Leighton Andrew Elliott ◽  
Nadia N. Ramdin ◽  
Joseph Vadakara

10599 Background: Pancreatic cancer is the 7th most common cause of cancer death worldwide and is projected to be the second leading cause of cancer death in the next decade. Personalized care is becoming more of a reality with pharmacological regimens targeting specific genetic mutations. In March 2019, the National Comprehensive Cancer Network (NCCN) guidelines were updated to recommend germline testing (GT) in all patients with pancreatic adenocarcinoma (PDAC) considering 1 in 10 may have a germline mutation (GM). The goal of this study was to quantify compliance with these recently updated guidelines. Methods: The electronic medical records and survivorship data of all patients diagnosed with PDAC between January 1, 2017 and October 1, 2020 were reviewed. April 1, 2019 was used as the transition point (TP) for guideline updates. Descriptive statistics for all variables were determined. The rate of ordered referrals to genetic counseling (GC), as well as completion rate, was calculated. Results: A total of 304 patients were diagnosed with PDAC during the study period (223 prior to the TP). A total of 54 patients were referred for GC and 41 had GT ordered. The rate of GC referrals ordered after the TP was significantly higher than before the TP (22/81, 26.6% vs. 32/223, 14.4%; p-value 0.010). Almost 60% of patients who had genetic evaluation had private insurance. The patients who completed GT were significantly more likely to have a documented family history of cancer (61.0% vs 4.2%; p-value <.0001Patients who completed GT had more problems on their problem list (median 10 vs 7, p = 0.001). The median overall survival (OS) for all patients in the study was 7.8 months (95% CI: 6.3-9.8). Conclusions: Overall compliance with the updated NCCN guidelines significantly improved; however, it was below 25%. This study showed that there may be some lingering bias toward GT in PDAC solely for those who have a family history of cancer. Although patients with stage IV PDAC have poor outcomes, GT may still improve surveillance for family members. The approval of olaparib in patients with BRCA1/2 mutations based on the POLO trial is likely to increase provider compliance as it provides a viable maintenance strategy in these patients. Patient complexity was unlikely to affect GT rate. Assessment of provider awareness was outside the scope of this study. There is need for continued advocacy for awareness and implementation of guidelines that highlight the importance of germline evaluation on prevention, surveillance, and treatment in pancreatic adenocarcinoma.


2018 ◽  
Vol 22 (1) ◽  
pp. 143-149 ◽  
Author(s):  
Subhayan Chattopadhyay ◽  
Otto Hemminki ◽  
Asta Försti ◽  
Kristina Sundquist ◽  
Jan Sundquist ◽  
...  

2005 ◽  
Vol 114 (4) ◽  
pp. 648-652 ◽  
Author(s):  
Eva Negri ◽  
Claudio Pelucchi ◽  
Renato Talamini ◽  
Maurizio Montella ◽  
Silvano Gallus ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document